Moderate to Severe Atopic DermatitisPhase 3NCT06468956
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
A Phase 3 study testing SHR-1819 in people with Moderate to Severe Atopic Dermatitis, run by Guangdong Hengrui Pharmaceutical Co., Ltd at 1 site in China.
Trial summary
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Moderate to Severe Atopic Dermatitis
- What is being tested?
- SHR-1819
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 652 participants
- Where
- 1 siteChina
- Study dates
- 14 Jun 2024to 26 Aug 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol；
- The age was ≥18 at the time of signing the informed consent and gender is unlimited;
- Atopic dermatitis at screening (according to the 2014 American Society of Dermatology guideline criteria, see Annex 1) and disease duration for at least 1 year before screening as judged by the investigator;
- EASI ≥ 16, IGA ≥ 3, BSA ≥ 10% during the screening and baseline periods;
- TCS was not optimal or not tolerated by the investigator.
Who cannot join
- Pregnant or lactating women;
- Major surgeries are planned for the duration of the study;
- History of previous atopic corneal conjunctivitis involving the cornea;
- History of clinically significant diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis;
- Subjects have had or are currently clinically significant diseases or abnormalities;
- Screening for people with a history of heavy alcohol consumption or substance abuse in the 3 months prior to screening;
Show all 10Show fewer
- The drug has been used in the previous 6 months;
- Screening of subjects with malignancy within the first 5 years (except completely cured cervical cancer in situ and non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma);
- Other comorbid (or co-occurring) skin disorders may be affected in the study evaluation;
- Any cause that the researchers believe would prevent the participants from participating in the study.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, 200040
About this study
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
- Conditions
- Moderate to Severe Atopic Dermatitis
- Being tested
- SHR-1819, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHR-1819Drug
SHR-1819 injection
PlaceboDrug
placebo
| Study group | Role | What they receive |
|---|---|---|
| SHR-1819 injection dose 1 | Experimental | Not described Receives: Drug: SHR-1819 |
| SHR-1819 injection dose 2 | Experimental | Not described Receives: Drug: SHR-1819 |
| placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥75% from baseline)
The extent of area is assessed using the EASI scale
Measured: up to 16 weeks
At week 16, the proportion of participants with an overall investigator assessment (IGA) score of 0 or 1 and a decrease of ≥2 points from baseline
The overall degree of improvement was assessed using the IGA scale
Measured: up to 16 week
Secondary outcomes (12)
The proportion of subjects whose weekly mean of the daily (PP-NRS) score decreased by 4 points from baseline at Week 16
Prtch improvement was assessed using the pruritus scale
Measured: up to 16 weeks
At week 16, the proportion of subjects who achieved EASI-90 (EASI score ≥90% lower than baseline)
The extent of area is assessed using the EASI scale
Measured: up to 16 weeks
Proportion of subjects reaching EASI-75 at other visit viewpoints
The extent of area is assessed using the EASI scale
Measured: up to 52 weeks
The proportion of subjects with IGA score of 0 or 1 and 2 points from baseline
The overall degree of improvement was assessed using the IGA scale
Measured: up to 52 weeks
Proproportion of subjects with a 2 points from baseline at each iGA
The overall degree of improvement was assessed using the IGA scale
Measured: up to 52 weeks
Percentage of change and change from baseline in EASI per visit viewpoint
The extent of area is assessed using the EASI scale
Measured: up to 52 weeks
Percentage of subjects with weekly mean PP-NRS scores of 3 points from baseline
Prtch improvement was assessed using the pruritus scale
Measured: up to 52 weeks
Percentage of change and change from baseline in the Skin Quality of Life Index Questionnaire (DLQI) score at each visit viewpoint
Subject quality of life was assessed using the DLQI scale
Measured: From the beginning of administration to the 52 week
Percentage of change from baseline in eczema self-assessment (POEM) scores at each viewpoint
Subject quality of life was assessed using the POEM scale
Measured: From the beginning of administration to the 52 week
The time of SHR-1819 in the serum
The concentration of SHR-1819 in plasma will be determined
Measured: From the beginning of administration to the 52th week
The concentration of SHR-1819 in serum: AUC
The concentration of SHR-1819 in plasma will be determined
Measured: From the beginning of administration to the 52th week
Changes in the level of IgE in the serum
Changes in the level of biomarkers in serum
Measured: From the beginning of administration to the 52th week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jun 2024
- Study start14 Jun 2024
- Primary completion26 Aug 2026
- Study completion26 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moderate to Severe Atopic DermatitisStudies of the same condition, open and under way.
- More trials run by Guangdong Hengrui Pharmaceutical Co., LtdThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 652 participants (actual)
Sponsor and investigators
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06468956
- Sponsor's protocol ID
- SHR-1819-301
- Status last verified
- Sep 2025
- First submitted
- 24 May 2024
- Last updated
- 3 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT06468956
- Acronym / sponsor ID
- SHR-1819-301
- Conditions
- Moderate to Severe Atopic Dermatitis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 652 participants (actual)
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 14 Jun 2024 (actual)
- Primary completion
- 26 Aug 2026 (actual)
- Study completion
- 26 Aug 2026 (actual)
- First posted
- 21 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| SHR-1819 injection dose 1 | Experimental | Drug: SHR-1819 |
| SHR-1819 injection dose 2 | Experimental | Drug: SHR-1819 |
| placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol；
- The age was ≥18 at the time of signing the informed consent and gender is unlimited;
- Atopic dermatitis at screening (according to the 2014 American Society of Dermatology guideline criteria, see Annex 1) and disease duration for at least 1 year before screening as judged by the investigator;
- EASI ≥ 16, IGA ≥ 3, BSA ≥ 10% during the screening and baseline periods;
- TCS was not optimal or not tolerated by the investigator.
Key exclusion criteria (10 listed)
- Pregnant or lactating women;
- Major surgeries are planned for the duration of the study;
- History of previous atopic corneal conjunctivitis involving the cornea;
- History of clinically significant diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis;
- Subjects have had or are currently clinically significant diseases or abnormalities;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHR-1819SHR-1819 injection | Drug | SHR-1819 injection dose 1, SHR-1819 injection dose 2 |
| Placeboplacebo | Drug | placebo |
Primary outcome
At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥75% from baseline)
Time frame: up to 16 weeks
The extent of area is assessed using the EASI scale
At week 16, the proportion of participants with an overall investigator assessment (IGA) score of 0 or 1 and a decrease of ≥2 points from baseline
Time frame: up to 16 week
The overall degree of improvement was assessed using the IGA scale
12 secondary outcomes
The proportion of subjects whose weekly mean of the daily (PP-NRS) score decreased by 4 points from baseline at Week 16
Time frame: up to 16 weeks
At week 16, the proportion of subjects who achieved EASI-90 (EASI score ≥90% lower than baseline)
Time frame: up to 16 weeks
Proportion of subjects reaching EASI-75 at other visit viewpoints
Time frame: up to 52 weeks
The proportion of subjects with IGA score of 0 or 1 and 2 points from baseline
Time frame: up to 52 weeks
Proproportion of subjects with a 2 points from baseline at each iGA
Time frame: up to 52 weeks
Percentage of change and change from baseline in EASI per visit viewpoint
Time frame: up to 52 weeks
Percentage of subjects with weekly mean PP-NRS scores of 3 points from baseline
Time frame: up to 52 weeks
Percentage of change and change from baseline in the Skin Quality of Life Index Questionnaire (DLQI) score at each visit viewpoint
Time frame: From the beginning of administration to the 52 week
Percentage of change from baseline in eczema self-assessment (POEM) scores at each viewpoint
Time frame: From the beginning of administration to the 52 week
The time of SHR-1819 in the serum
Time frame: From the beginning of administration to the 52th week
The concentration of SHR-1819 in serum: AUC
Time frame: From the beginning of administration to the 52th week
Changes in the level of IgE in the serum
Time frame: From the beginning of administration to the 52th week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Moderate to Severe Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
RecruitingPhase 3
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Atopic Dermatitis, Atopic Dermatitis (AD)
RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Atopic Dermatitis
RecruitingPhase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Atopic Dermatitis, Eczema, Atopic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing SHR-1819 in people with Moderate to Severe Atopic Dermatitis, run by Guangdong Hengrui Pharmaceutical Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥75% from baseline) (time frame: up to 16 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.